Physician profile
Steve W Su
NPI 1033187133
$2,915.35
in general payments reported to CMS, 2019-2025
30 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $118 · 2021: $84.26 · 2022: $448 · 2023: $602 · 2024: $737 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878 · Education: $26.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.83 |
| Education | $26.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $506.77 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Astrazeneca Pharmaceuticals LP | $363.88 | 2019-2024 | Farxiga, Lokelma, Evusheld |
| Mallinckrodt Hospital Products INC. | $242.98 | 2022-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $233.93 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $153.03 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.34 | 2022-2025 | |
| Glaxosmithkline, LLC. | $134.20 | 2021-2023 | Benlysta |
| Daiichi Sankyo INC. | $94.33 | 2019-2024 | Injectafer |
| Kyowa Kirin, INC. | $92.13 | 2023-2025 | Crysvita |
| Vifor Pharma, INC. | $87.78 | 2019-2024 | Veltassa |
| Akebia Therapeutics INC | $86.59 | 2019-2025 | Vafseo |
| Genzyme Corporation | $79.54 | 2019-2024 | |
| Fresenius USA Marketing, INC. | $72.97 | 2019-2022 | |
| Scpharmaceuticals INC. | $71.23 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $66.75 | 2023-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $64.07 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $60.09 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.44 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $47.55 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $40.47 | 2019-2020 | |
| Lilly USA, LLC | $29.24 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $28.98 | 2024 | Purified Cortrophin Gel |
| Shield Therapeutics INC | $27.81 | 2025 | |
| Shire North American Group INC | $21.69 | 2019 | |
| Abbott Laboratories | $20.65 | 2023 | Freestyle Libre 3 |
| Argon Medical Devices, INC. | $20.60 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.02 | 2019 | |
| Nxstage Medical, INC. | $19.91 | 2025 | Nxstage System One |
| Mallinckrodt Enterprises LLC | $15.75 | 2019 | |
| Genentech USA, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.